RxDoctor Payments Data

Megan Koenig, PA

Physician Assistant · Columbia, MONPI 1447830492

Payments from drug & device makers

$941in general payments, 2019–2025

Across 19 payments — averaging $49.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$322
  • Phathom Pharmaceuticals, Inc.$127
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$120
  • Ardelyx, Inc.$119
  • Axonics, Inc.$85
  • Takeda Pharmaceuticals U.S.A., Inc.$54
  • plus $113 from 4 others

What the payments were for

  • Food & beverage$941100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$941 in reported general payments places this provider in the 70th percentile of 1,380 physician assistant providers in Missouri.

See all physician assistant providers in Missouri

Medicare billing

Part B allowed, 2024
$28,823
Medicare patients
224
Services billed
515

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab42$1,102,659
Humira(Cf) PenAdalimumab45$419,912
CreonLipase/Protease/Amylase77$208,525
Entyvio PenVedolizumab22$171,180
XifaxanRifaximin51$159,053
LinzessLinaclotide134$113,131
ZenpepLipase/Protease/Amylase15$65,014
Mesalamine33$16,396
Lansoprazole36$8,611
TrulancePlecanatide12$6,598
MovantikNaloxegol Oxalate12$4,755
Mesalamine ErMesalamine13$4,701
Esomeprazole Magnesium44$4,608
Sucralfate38$3,931
Ursodiol12$3,094

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$322$321,656211 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance$120$165,65163 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,380 physician assistant providers in Missouri.

Other physician assistant in Columbia

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →